These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 30692213)

  • 21. Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kδ inhibitors.
    Gadi D; Martindale SP; Chiu PY; Khalsa J; Chen PH; Fernandes SM; Wang Z; Tyekucheva S; Machado JH; Fisher DC; Armand P; Davids MS; Rodig S; Sherry B; Brown JR
    Blood Cancer J; 2023 Feb; 13(1):22. PubMed ID: 36732326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PKC-θ is an important driver of fluoride-induced immune imbalance of regulatory T cells/effector T cells.
    Zhu S; Liu B; Fu G; Yang L; Wei D; Zhang L; Zhang Q; Gao Y; Sun D; Wei W
    Sci Total Environ; 2024 Jul; 934():173081. PubMed ID: 38754514
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of dual inhibitors of the immune cell PI3Ks p110delta and p110gamma: a prototype for new anti-inflammatory drugs.
    Williams O; Houseman BT; Kunkel EJ; Aizenstein B; Hoffman R; Knight ZA; Shokat KM
    Chem Biol; 2010 Feb; 17(2):123-34. PubMed ID: 20189103
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Idelalisib-Induced Pneumonitis in Chronic Lymphocytic Leukemia.
    Ravi SN; Choi IW; Ngapgue EK; Stroiney AG; Miranda CJ
    Cureus; 2024 May; 16(5):e59541. PubMed ID: 38826911
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of novel pyrido[3,2-d]pyrimidine derivatives as selective and potent PI3Kδ inhibitors.
    Bai H; Sun J; Lei H; Zhang SQ; Yuan B; Ma M; Xin M
    Drug Dev Res; 2023 Dec; 84(8):1709-1723. PubMed ID: 37732677
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of Novel Azaindoles as Potent and Selective PI3Kδ Inhibitors for Treatment of Multiple Sclerosis.
    Yu M; Wang X; Tang Y; Wang L; Hu X; Weng Q; Wang J; Cui S
    J Med Chem; 2024 Jun; 67(11):9628-9644. PubMed ID: 38754045
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PI3K Isoform Immunotherapy for Solid Tumours.
    Scott J; Rees L; Gallimore A; Lauder SN
    Curr Top Microbiol Immunol; 2022; 436():369-392. PubMed ID: 36243853
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer.
    Ali K; Soond DR; Pineiro R; Hagemann T; Pearce W; Lim EL; Bouabe H; Scudamore CL; Hancox T; Maecker H; Friedman L; Turner M; Okkenhaug K; Vanhaesebroeck B
    Nature; 2014 Jun; 510(7505):407-411. PubMed ID: 24919154
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pegylated-liposomes increase the efficacy of Idelalisib in lymphoma B-cells.
    Maroni G; Tomassi E; Valenti D; Fernàndez-Busquets X; Pucci L; Levantini E; Caddeo C
    Int J Pharm; 2024 May; 657():124144. PubMed ID: 38653342
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative systems pharmacology model-based investigation of adverse gastrointestinal events associated with prolonged treatment with PI3-kinase inhibitors.
    Gadkar K; Friedrich C; Hurez V; Ruiz ML; Dickmann L; Kumar Jolly M; Schutt L; Jin J; Ware JA; Ramanujan S
    CPT Pharmacometrics Syst Pharmacol; 2022 May; 11(5):616-627. PubMed ID: 34850607
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PI3Kδ Mediates Fibrosis by Patient-Derived Vitreous.
    Liu D; Yan B; Yin Y; Chen F; Guo C; Li Q; Liu J; Pu L; Wu W; Luo J
    Lab Invest; 2024 Apr; 104(4):102026. PubMed ID: 38307209
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activated PI3Kδ specifically perturbs mouse Treg homeostasis and function leading to immune dysregulation.
    Singh AK; Qureshah FA; Drow T; Hou B; Rawlings DJ
    bioRxiv; 2023 Dec; ():. PubMed ID: 38187650
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs.
    Eschweiler S; Ramírez-Suástegui C; Li Y; King E; Chudley L; Thomas J; Wood O; von Witzleben A; Jeffrey D; McCann K; Simon H; Mondal M; Wang A; Dicker M; Lopez-Guadamillas E; Chou TF; Dobbs NA; Essame L; Acton G; Kelly F; Halbert G; Sacco JJ; Schache AG; Shaw R; McCaul JA; Paterson C; Davies JH; Brennan PA; Singh RP; Loadman PM; Wilson W; Hackshaw A; Seumois G; Okkenhaug K; Thomas GJ; Jones TM; Ay F; Friberg G; Kronenberg M; Vanhaesebroeck B; Vijayanand P; Ottensmeier CH
    Nature; 2022 May; 605(7911):741-746. PubMed ID: 35508656
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular Insight into Drug Resistance Mechanism Conferred by Aberrant
    Ha S; Wang BD
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831678
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of the PI3K inhibitor Idelalisib with the conventional cytostatics cytarabine and dexamethasone leads to changes in pathway activation that induce anti-proliferative effects in B lymphoblastic leukaemia cell lines.
    Sklarz LM; Gladbach YS; Ernst M; Hamed M; Roolf C; Sender S; Beck J; Schütz E; Fischer S; Struckmann S; Junghanss C; Fuellen G; Murua Escobar H
    Cancer Cell Int; 2020; 20():390. PubMed ID: 32817744
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of idelalisib in chronic lymphocytic leukemia and follicular lymphoma disclose better outcomes for patients with lower exposure.
    Despas F; Chaouki M; de Barros S; Bonneau B; Allal B; Guillermet-Guibert J; Ysebaert L
    Leuk Lymphoma; 2024 Sep; 65(9):1378-1380. PubMed ID: 38747179
    [No Abstract]   [Full Text] [Related]  

  • 37. Correction: Multiply restimulated human cord blood-derived Tregs maintain stabilized phenotype and suppressive function and predict their therapeutic effects on autoimmune diabetes.
    Bi Y; Kong R; Peng Y; Cai D; Zhang Y; Yang F; Li X; Deng W; Liu F; He B; Cao C; Deng C; Tang X; Fan L; Yu H; Zhou Z
    Diabetol Metab Syndr; 2024 Jul; 16(1):148. PubMed ID: 38965639
    [No Abstract]   [Full Text] [Related]  

  • 38. Phosphoinositide 3-kinase δ is a regulatory T-cell target in cancer immunotherapy.
    Lim EL; Okkenhaug K
    Immunology; 2019 Jul; 157(3):210-218. PubMed ID: 31107985
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.